Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with
Alleles
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Azetidines
/ administration & dosage
Biomarkers, Tumor
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Gene Expression Profiling
Genomics
/ methods
Humans
Melanoma
/ drug therapy
Mutation
Piperidines
/ administration & dosage
Proto-Oncogene Proteins B-raf
/ genetics
Randomized Controlled Trials as Topic
Retrospective Studies
Treatment Outcome
Vemurafenib
/ administration & dosage
Exome Sequencing
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
received:
14
03
2018
revised:
01
11
2018
accepted:
22
02
2019
pubmed:
3
3
2019
medline:
7
7
2020
entrez:
3
3
2019
Statut:
ppublish
Résumé
Previous investigations identified transcriptional signatures associated with innate resistance to anti-programmed cell death protein 1 therapy in melanoma. This analysis aimed to increase understanding of the role of baseline genetic features in the variability of response to BRAF and MEK inhibitor therapy for This exploratory analysis compared genomic features, using whole-exome and RNA sequencing, of baseline tumors from patients who had complete response versus rapid progression (disease progression at first postbaseline assessment) on treatment with cobimetinib combined with vemurafenib or vemurafenib alone. Associations of gene expression with progression-free survival or overall survival were assessed by Cox proportional hazards modeling. Whole-exome sequencing showed that These findings suggest that enriched immune infiltration might be a shared feature favoring response to both targeted and immune therapies, while features of innate resistance to targeted and immune therapies were distinct.
Identifiants
pubmed: 30824584
pii: 1078-0432.CCR-18-0720
doi: 10.1158/1078-0432.CCR-18-0720
pmc: PMC8083896
mid: NIHMS1692052
doi:
Substances chimiques
Azetidines
0
Biomarkers, Tumor
0
Piperidines
0
Vemurafenib
207SMY3FQT
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
cobimetinib
ER29L26N1X
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3239-3246Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Oncoimmunology. 2013 Aug 1;2(8):e25218
pubmed: 24167759
N Engl J Med. 2012 Feb 23;366(8):707-14
pubmed: 22356324
Cancer Res. 2014 Apr 15;74(8):2340-50
pubmed: 24576830
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Cancer Discov. 2014 Jan;4(1):80-93
pubmed: 24265155
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
J Clin Oncol. 2013 May 10;31(14):1767-74
pubmed: 23569304
Clin Cancer Res. 2012 Mar 1;18(5):1386-94
pubmed: 22156613
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cancer Discov. 2014 Jul;4(7):816-27
pubmed: 24771846
Cancer Res. 2008 Feb 1;68(3):650-6
pubmed: 18245463
Lancet. 2015 Aug 1;386(9992):444-51
pubmed: 26037941
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nucleic Acids Res. 2015 Mar 31;43(6):e39
pubmed: 25618849
Clin Cancer Res. 2012 Oct 1;18(19):5329-40
pubmed: 22850568
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Bioinformatics. 2010 Apr 1;26(7):873-81
pubmed: 20147302
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Exp Med. 2006 Jul 10;203(7):1651-6
pubmed: 16801397
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Lancet Oncol. 2014 Aug;15(9):954-65
pubmed: 25037139
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Nucleic Acids Res. 2012 Dec;40(22):11189-201
pubmed: 23066108
Lancet Oncol. 2012 Oct;13(10):e409; author reply e409-10
pubmed: 23026823
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Cancer. 2017 Apr 15;123(8):1372-1381
pubmed: 27911979
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Lancet Oncol. 2014 Mar;15(3):323-32
pubmed: 24508103
Cancer Discov. 2013 Mar;3(3):338-49
pubmed: 23171796
Clin Cancer Res. 2013 Mar 1;19(5):1225-31
pubmed: 23307859